TITLE

To prevent MI, men must take aspirin at least every other day (but should they?)

PUB. DATE
April 1995
SOURCE
Modern Medicine;Apr95, Vol. 63 Issue 4, p51
SOURCE TYPE
Periodical
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the study `Adherence to aspirin in the prevention of myocardial infarction: The Physicians' Health Study,' by R.J. Glynn et al from the December 12, 1994 issue of the journal `Archives of Internal Medicine.'
ACCESSION #
9505100651

 

Related Articles

  • Aspirin for Primary Prevention of Coronary Events. Lauer, Michael S. // New England Journal of Medicine;5/9/2002, Vol. 346 Issue 19, p1468 

    Focuses on the use of aspirin for primary prevention of coronary events such as myocardial infarction, highlighted through the case vignette of a 45-year old man with a strong family history of premature heart disease. Strategies and evidence; Areas of uncertainty; Guidelines; Conclusions and...

  • Aspirin and warfarin best for primary prevention of heart... Kmietowicz, Zosia // BMJ: British Medical Journal (International Edition);01/31/98, Vol. 316 Issue 7128, p330 

    Details the study of the Medical Research Council on the effectiveness of warfarin and aspirin on preventing heart attacks. Methodology used in the study; Findings of the study; Account on the warning given by Freek Verheught, professor from the University Hospital of Nijmegen, on aspirin and...

  • Could recommendations about aspirin prophylaxis enhance colorectal cancer screening programmes? Morgan, Gareth; Elwood, Peter // European Journal of Public Health;Dec2009, Vol. 19 Issue 6, p576 

    The article analyzes a study which examined the effectiveness of aspirin prophylaxis in enhancing colorectal cancer screening programmes. The health benefits of aspirin are noted, including reducing the risk of vascular events and myocardial infarction. The study observed that the benefits of...

  • Clopidogrel in ischemic heart disease: A critical appraisal. Al-Otaiby, Mohammed A.; Al-Moghairi, Abdulrahman M. // Health (1949-4998);Mar2013, Vol. 5 Issue 3, p465 

    Aspirin and clopidogrel are the commonest dual antiplatelet agents being used in the secondary prevention of cardiovascular disease. In high risk patients with coronary heart disease, the use of aspirin was associated with a significant risk reduction of myocardial infarction, stroke and...

  • Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials Sanmuganathan, P S; Ghahramani, P; Jackson, P R; Wallis, E J; Ramsay, L E // Heart;Mar2001, Vol. 85 Issue 3, p265 

    The article presents a study which investigates the safety and benefit of aspirin used as primary prevention of coronary heart disease. The study was conducted through meta-analysis of four randomised controlled trials of aspirin. The study reveals that aspirin used in preventing coronary heart...

  • Lifestyle changes reduce cardiovascular risk. Ryan, Patricia // Research Review (International Council on Active Aging);Apr2012, Vol. 12 Issue 13, p4 

    The article discusses the results of Heart of New Ulm Project, aimed at reducing heart attacks and coronary heart disease in New Ulm, Minnesota, that found reductions in factors including smoking, stress levels and hypertension, as well as in hyperlipidemia, and fasting glucose.

  • Modular prevention of heart disease following acute coronary syndrome (ACS) [ISRCTN42984084]. Redfern, Julie; Ellis, Elizabeth; Briffa, Tom; Freedman, SB // BMC Cardiovascular Disorders;2006, Vol. 6, p26 

    Background: Coronary heart disease (CHD) is a major cause of morbidity and mortality in Australia and it is recommended that all persons with unstable angina (UA) or myocardial infarction (MI) participate in secondary prevention as offered in cardiac rehabilitation (CR) programs. However, the...

  • Cardiovascular disease: microRNA protects the heart. Kingwell, Katie // Nature Reviews Drug Discovery;Feb2011, Vol. 10 Issue 2, p98 

    The article discusses research concerning the reduction of myocardial infarction's effects through microRNA (miRNA) miR-499. It references the study "mIr-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1," by J.-X. Wang and colleagues in the 2011 issue...

  • Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. Bhatt, Deepak L.; Fox, Keith A.A.; Hacke, Werner; Berger, Peter B.; Black, Henry R.; Boden, William E.; Cacoub, Patrice; Cohen, Eric A.; Creager, Mark A.; Easton, J. Donald; Flather, Marcus D.; Haffner, Steven M.; Hamm, Christian W.; Hankey, Graeme J.; Johnston, S. Claiborne; Mak, Koon-Hou; Mas, Jean-Louis; Montalescot, Gilles; Pearson, Thomas A.; Steg, P. Gabriel // New England Journal of Medicine;4/20/2006, Vol. 354 Issue 16, p1706 

    Background: Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events. Methods: We randomly assigned 15,603 patients with either clinically evident cardiovascular disease or multiple risk...

  • ST-Elevation Myocardial Infarction: Preventive Percutaneous Coronary Intervention in the Non-Culprit Vessel. Triantafyllou, Konstantinos // Hospital Chronicles;2014, Vol. 9 Issue 3, p167 

    Patients with ST-segment elevation myocardial infarction (STEMI) and multi-vessel coronary disease (MVD) have poorer outcomes after primary percutaneous coronary intervention (PCI) compared to those with one-vessel disease. Current STEMI guidelines recommend revascularization of the infarct...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics